About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Deerfield Supports Melinta Therapeutics Acquisition of The Medicines Company’s Infectious Disease Business with a $240 million Commitment to Melinta and a $100 million Commitment to The Medicines Company

NEW YORK, NEW YORK – November 29, 2017 – Deerfield Management Company announced today it has committed to provide up to $240 million in debt and equity financing to Melinta Therapeutics (NASDAQ: MLNT) and up to $100 million in debt financing to The Medicines Company (NASDAQ: MDCO) in connection with Melinta’s acquisition of the infectious disease business from The Medicines Company. The acquisition includes the purchase of global rights for Vabomere, Orbactiv and Minocin IV and the business unit supporting those products.

Upon the closing of the acquisition, Deerfield will provide $190 million in debt and equity funding to Melinta. Furthermore, Melinta will have the option to draw up to $50 million of debt within 24 months of the closing of the transaction subject to achieving certain sales thresholds. In addition, Deerfield has agreed to provide up to $100 million in drawable debt financing to The Medicines Company. These financings are subject to the terms and conditions of the commitment letters entered into by Deerfield with each of Melinta and The Medicines Company.

“We are proud to be Melinta’s partner as it emerges as a leading infectious disease company,” stated Jonathan Leff, Partner of Deerfield. “This transaction is a credit to Melinta and The Medicines Company for their creative efforts to achieve a result that satisfies the strategic objectives of each company.”

Dan Wechsler, Melinta’s President and Chief Executive Officer commented, “Deerfield was critical to this transaction. Its flexible approach and deep understanding of the infectious disease market place enabled them to act quickly and to provide a customized financing solution to meet the needs of Melinta and The Medicines Company. We also benefited greatly from Deerfield’s support and advice in the structuring and negotiation of the transaction.”

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy. For more information, please


Deerfield Management Company
Karen Heidelberger, 212‐692‐7140
[email protected]